Our science has outpaced our policies for #GeneTherapy, #GeneEditing and other targeted therapies that can be developed for some diseases with few or no treatments. Read this survey from investors and innovators including our CEO Emil Kakkis that highlights the challenges in the regulatory pathway for cell and gene therapies: https://lnkd.in/eQQi2SDU
Strategic Biotech Leader | Medical Affairs | RWE & HEOR | Clin Dev | BD | US Payers & HCS | Cell & Gene Therapy | Master Communicator & Story Teller | Build High Impact Teams | Vision-casting
4dAs a physician in biotech, I strongly support resolving regulatory inefficiencies to encourage investment and accelerate patient access to cell and gene therapies. Delays in approvals not only stifle innovation but also extend the wait for patients. Strengthening FDA-biotech collaboration and providing regulatory consistency are essential to getting C&G therapies to patients faster. Thanks for sharing, Ultragenyx!